Immune research progress of Slit2-Robo signaling axis in chronic obstructive pulmonary disease: a narrative review Authors: Weiwei An, Dejin Liang Published: 2026 ABSTRACT Background and ObjectiveChronic obstructive pulmonary disease (COPD) is a leading cause of global morbidity and mortality, with smoking being its primary etiological factor. The Slit2-roundabout (Robo) signaling axis is recognized for its pivotal roles in guiding cell migration and regulating immune responses. Recently, its involvement in smoking-related lung inflammation and tissue remodeling has garnered increasing attention. The objective of this narrative review is to synthesize current evidence on the immune regulatory functions of the Slit2-Robo axis in the pathogenesis of COPD, and to explore its translational potential.MethodsA literature search was conducted in the PubMed and China National Knowledge Infrastructure (CNKI) databases. Search terms included “Slit2”, “Robo”, “chronic obstructive pulmonary disease”, “inflammation”, “immune cell migration”, and “tissue remodeling”. Publications from database inception through March 2025 were reviewed without language restrictions, with a focus on studies elucidating the mechanistic role of the Slit2-Robo signaling axis in smoking-related COPD.Key Content and FindingsThe Slit2-Robo axis is implicated in multiple processes central to COPD pathophysiology. Key findings include: (I) it modulates the recruitment, activation, and function of key immune cells (e.g., neutrophils, macrophages, lymphocytes) in the lung in response to smoke exposure. (II) It interacts with inflammatory signaling pathways, influencing the production of cytokines and chemokines that sustain chronic inflammation. (III) Beyond inflammation, this axis plays a dual role in tissue repair and remodeling, potentially affecting epithelial integrity, angiogenesis, and fibrotic processes, which are hallmarks of advanced COPD.ConclusionsCurrent evidence suggests that the Slit2-Robo signaling axis may be an important regulator of immune and repair responses in smoking-induced COPD. However, the current evidence base remains limited, as most findings are derived from preclinical models and have not yet been sufficiently validated in human COPD. In addition, heterogeneity across study designs and experimental endpoints contributes to uncertainty regarding its translational significance. Further clinical and translational studies are needed to clarify its cell-specific and stage-specific roles, assess its biomarker value, and determine the feasibility of therapeutic targeting in COPD. Introduction Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable chronic respiratory disorder characterized by persistent airflow limitation and chronic airway inflammation. Under physiological conditions, airway homeostasis is maintained by a multilayered defense system that acts as a critical barrier against invading pathogens, allowing timely recognition and clearance of microorganisms entering the respiratory tract while limiting infection and secondary tissue injury (1). By contrast, chronic exposure to cigarette smoke (CS) promotes sustained release of chemotactic mediators, including interleukin-8 (IL-8), thereby driving aberrant recruitment and pathological accumulation of neutrophils and other inflammatory cells in the airways and progressively converting protective immune responses into a chronic and dysregulated inflammatory process (1,2). Although macrophages, lymphocytes, and other immune cell populations all participate in the inflammatory network of COPD, neutrophils are particularly notable because of their abundance and close association with disease pathogenesis. As major effector cells of innate immunity, neutrophils mediate pathogen clearance through phagocytosis, reactive oxygen species (ROS) production, and degranulation. Under inflammatory conditions, they adhere to the vascular endothelium, undergo transendothelial migration, and follow chemotactic gradients into injured tissue, where they release antimicrobial peptides, ROS, and proteolytic enzymes. Nevertheless, persistent or excessive neutrophil activation can produce marked bystander injury, thereby aggravating airway and parenchymal destruction and contributing to emphysema development, mucus hypersecretion, and small-airway remodeling (3-6). Therefore, sustained neutrophilic infiltration and aberrant activation are not only hallmarks of chronic inflammation in COPD but also major drivers of structural lung damage and progressive functional decline. Available evidence indicates that peripheral blood neutrophilia and functional reprogramming may already be present in early-stage COPD. During acute exacerbations, airway neutrophil burden increases further and correlates with more severe airflow limitation, dynamic hyperinflation, and worsening dyspnea. Moreover, tobacco exposure may shift neutrophil death from apoptosis toward necrosis, thereby secondarily activating airway epithelial inflammatory responses and establishing a vicious cycle of neutrophil recruitment, tissue injury, and inflammatory re-amplification. Elevated peripheral blood neutrophil counts have likewise been associated with more frequent acute exacerbations and poorer clinical outcomes, including increased mortality risk, in patients with COPD (2,3,7). The Slit2-roundabout (Robo) signaling pathway was initially recognized for its role in neuronal axon guidance. Robo receptors comprise a family of transmembrane receptors with tissue- and cell type-specific expression patterns and functional specialization; in studies of immune cell migration and inflammatory regulation, Robo is most commonly discussed as the principal receptor for Slit2. Increasing evidence indicates that the Slit2-Robo signaling axis contributes to the fine-tuned regulation of pulmonary inflammatory responses, immune cell trafficking, and tissue repair (8,9). The interaction between Slit2 and Robo may influence both the magnitude and spatial extent of inflammatory responses and, additionally, may shape the initiation and progression of chronic inflammation by modulating the recruitment and effector functions of key immune cells, including neutrophils and macrophages (10). Accordingly, investigating the roles and mechanisms of the Slit2-Robo signaling axis in COPD from the perspective of immunoregulatory control of cell migration may offer new insights into tobacco-related lung disease and highlight potential translational therapeutic targets. Clinically, anti-inflammatory agents such as aspirin and glucocorticoids have been used to mitigate neutrophil-mediated tissue injury, primarily by suppressing activation of transcription factors (e.g., NF-κB) and thereby reducing proinflammatory cytokine levels (11). In addition, strategies that selectively disrupt neutrophil chemotactic pathways have shown benefit in animal studies and early-phase clinical investigations, and several chemokine receptor antagonists or neutralizing antibodies are currently being evaluated across clinical trial phases (12). However, given the substantial complexity and redundancy of chemotactic networks, single-target interventions may be insufficient to achieve durable efficacy; combination regimens or multi-target blockade may therefore offer greater clinical advantage. The multi-layered regulatory potential centered on the Slit2-Robo axis thus introduces a plausible avenue for alleviating neutrophil-driven lung tissue injury. Across multiple cell types, the Slit2-Robo1 signaling pathway has been shown to exert broad anti-migratory effects. Beyond neurons, this pathway markedly suppresses the motility of vascular smooth muscle cells, breast cancer cells, and brain tumor cells (13,14). More importantly, Slit2-mediated inhibition of cell migration is not restricted to a single class of chemotactic stimuli; rather, it can concurrently attenuate migration toward platelet-derived growth factor (PDGF) and the chemokines CXCL12 and CCL2 (14-17). This feature suggests broad implications in immunoregulation, tumor metastasis, and vascular remodeling and underscores the therapeutic potential of targeting Slit2-Robo1. In the context of angiogenesis, Slit2 can effectively inhibit neovascularization by disrupting aberrant endothelial chemotaxis toward vascular endothelial growth factor (VEGF) (18). Although the anti-migratory effects of Slit2 have been well documented, its regulatory mechanisms in inflammatory settings—particularly with respect to neutrophil migration—remain unclear. Directed neutrophil trafficking to inflammatory foci is a double-edged sword for tissue injury and repair; therefore, precisely restraining aberrant migration is of substantial therapeutic relevance (9,19). Available evidence indicates that Slit2 blocks cell migration by inhibiting Cdc42 activation (20). As a key regulator of cell polarity and directional movement, loss of Cdc42 function markedly impairs neutrophil locomotion along chemotactic gradients (21,22). Collectively, these findings suggest that Slit2-Robo-mediated Cdc42 inactivation may represent a central mechanism for constraining excessive neutrophil-driven inflammatory responses. In recent years, accumulating evidence has indicated that neutrophil extracellular traps (NETs) play a pivotal role in tobacco-related chronic pulmonary inflammation. NETs are an innate immune mechanism whereby neutrophils release web-like DNA structures to entrap pathogens, serving an important defensive function during acute infection (23,24). However, emerging data suggest that NET formation is not only protective in acute infection but can also amplify and sustain inflammatory responses in lung disease driven by chronic tobacco exposure, thereby exacerbating pathological progression. Both clinical observations and animal studies have demonstrated that chronic smoking markedly promotes NET generation, and this process is closely associated with the progression of chronic lung diseases such as COPD (25). The DNA scaffold released by NETs can interact with diverse inflammatory mediators, cytokines, and proteolytic enzymes, collectively augmenting tobacco-induced persistent inflammation. Nevertheless, the molecular regulatory networks governing NET formation under chronic tobacco exposure remain incompletely defined. Available data implicate Toll-like receptor (TLR) signaling, oxidative stress, and selected cytokines in the regulation of NET generation; however, the underlying mechanisms and their interrelationships require further investigation. Accordingly, systematically delineating NET formation and its regulatory mechanisms during chronic tobacco exposure is important for clarifying the immunologic basis of tobacco-related lung diseases, including COPD. Future research should prioritize identifying the key molecules and signaling pathways that drive NET generation, defining the roles of NETs in sustaining inflammation and promoting tissue injury, and evaluating the clinical feasibility and safety of NET-targeted interventions. Such efforts would provide a rationale for developing new intervention strategies and therapeutic approaches and may ultimately inform improved treatment of tobacco-related diseases. We present this article in accordance with the Narrative Review reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0136/rc). Methods This narrative review synthesized evidence from previously published studies identified through a systematic search of PubMed and the China National Knowledge Infrastructure (CNKI) databases. Search terms included “Slit2”, “Robo”, “chronic obstructive pulmonary disease”, “inflammation”, “immune cell migration”, and “tissue remodeling”. Publications from database inception through March 2025 were comprehensively evaluated, with no language restrictions. Studies were screened for relevance to advances in understanding the Slit2-Robo axis in smoking-related COPD, including inflammation, immune cell trafficking, NET formation, and tissue repair. The detailed search strategy is presented in Table 1, and all included articles are listed in the reference section. Table 1Search strategyItemsSpecificationDate of search1 March 2025 to 1 November 2025Databases searchedPubMed and CNKISearch terms used“Slit2”, “Robo”, “chronic obstructive pulmonary disease”, “inflammation”, “immune cell migration”, and “tissue remodeling”TimeframeFrom database inception to March 2025Inclusion criteriaStudy type: original article, review, clinical studies, systematic reviews/meta-analyses; language: no language restrictionsSelection processStudy selection and full-text articles were assessed by W.A. and D.L.CNKI, China National Knowledge Infrastructure; Robo, roundabout. Search strategy CNKI, China National Knowledge Infrastructure; Robo, roundabout. Neutrophil NETs play an important role in tobacco-related chronic pulmonary inflammation Structure and composition of neutrophil NETs Neutrophils are the most abundant leukocyte population in mammals and constitute a central component of the innate immune system, playing a critical role in host defense against microbial invasion. Neutrophils primarily eliminate microbes through three major mechanisms: phagocytosis, ROS generation, and degranulation. Upon inflammatory stimulation, neutrophils undergo chemotactic migration from the circulation to sites of inflammation and exert bactericidal effects through secretion of antimicrobial peptides, ROS production, and phagocytosis (2,6). In 2004, Brinkmann and colleagues first described a previously unrecognized antimicrobial mechanism of neutrophils—“NETosis”, namely the formation of NETs—induced by inflammatory stimuli such as lipopolysaccharide (LPS), IL-8, or phorbol 12-myristate 13-acetate (PMA) (3,26). Following activation, neutrophils progressively release granular proteins and chromatin, with NET formation initiating approximately 10 minutes after stimulation. These extracellular fibrous structures can bind both Gram-positive and Gram-negative bacteria, thereby limiting microbial dissemination and enhancing antimicrobial defense (27). NETs are primarily composed of a DNA backbone decorated with cytotoxic granule-derived proteins and enzymes, including histones (e.g., H1, H2A, H2B, H3, and H4), neutrophil elastase (NE), myeloperoxidase (MPO), and components of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system (11,12,26). In endotoxemia models or murine sepsis models induced by cecal ligation and puncture (CLP), plasma NET levels are markedly increased; abundant NETs have also been observed in human acute inflammatory conditions such as acute appendicitis and experimental dysentery. In patients with severe acute kidney injury (AKI) complicated by sepsis, serum NET levels are even higher and correlate closely with sepsis severity and biomarkers of organ injury (28,29). Previous studies have demonstrated that neutrophils can release NETs through three distinct mechanisms, during which the neutrophils themselves remain viable. This destructive cellular process is distinct from classical apoptosis or necrosis. Following chromatin decondensation, intracellular organelle membranes progressively disintegrate, resulting in the mixing of cytoplasmic and nuclear contents, and ultimately in the rupture of the plasma membrane, which enables the release of NETs (12,28). Neutrophils release antimicrobial factors, namely granule-derived components, into the extracellular milieu to form NETs, which subsequently immobilize and kill bacteria outside the cell. Scanning electron microscopy has revealed that NETs exhibit smooth, elongated fibers with diameters of approximately 15–17 nm, interspersed with globular domains of roughly 25 nm, none of which are surrounded by membranes (26). The DNA-associated proteins within NETs originate predominantly from azurophilic granules, but also from selected proteins of specific secondary and tertiary granules, such as lactoferrin and gelatinase. Evidence indicates that the diverse protein composition of NETs confers specificity to their antimicrobial activity, with NE being particularly effective against Gram-positive bacteria. This enzyme, together with H2A-H2B-DNA complexes, is predominantly localized within the globular domains of NETs. The role of neutrophil NETs in chronic lung inflammation In recent years, accumulating evidence has gradually delineated the “double-edged sword” role of NETs in immune regulation. On the one hand, NETs exert a crucial antimicrobial function within the innate immune system; on the other hand, their excessive formation or dysregulated clearance may precipitate tissue injury. In autoimmune diseases, sterile inflammatory conditions, and atherosclerosis, the pro-inflammatory properties of NETs have attracted substantial attention (30). Previous reports have shown that chronic inflammatory states such as preeclampsia, small-vessel vasculitis, and systemic lupus erythematosus are closely associated with excessive NET accumulation or impaired NET clearance. In 2015, it was first reported that NET formation in the lungs of patients with COPD is markedly increased both during the stable phase and in episodes of acute exacerbation, and that this phenomenon strongly correlates with the frequency of exacerbations and the severity of lung function impairment (21). Subsequent investigations have demonstrated that NETs exert a dose-dependent cytotoxic effect on human alveolar epithelial cells, and that enzymatic degradation of DNA does not attenuate this cytotoxicity, suggesting that both the DNA backbone and associated protein components may participate in the injurious process (13,17). Among the constituents of NETs, histone H3 is one of the most abundant proteins. It forms stable complexes with DNA and is relatively resistant to degradation by anti-histone antibodies or enzymatic digestion, thereby amplifying the cytotoxic potential of NETs (14). MPO is another critical component of NETs. By catalyzing the conversion of hydrogen peroxide into hypochlorous acid, MPO enhances the antimicrobial activity of NETs; however, this process may concurrently induce collateral damage to adjacent tissues and has been implicated as a key mediator in pulmonary inflammation and injury (14,31). Experimental data indicate that MPO can activate caspase-3 and induce apoptosis in HL-60 leukemia cells (32), and can promote DNA strand breaks in pulmonary epithelial cells (15). In vitro, pretreatment of NETs with MPO inhibitors partially attenuates NET-induced epithelial cytotoxicity, indicating that MPO plays a pivotal role in NET-mediated tissue damage. NE, as one of the key components of NETs, plays an important role in antimicrobial defense, but it can also mediate tissue injury, particularly by degrading extracellular matrix components and amplifying inflammatory responses. In LPS-challenged mice, elevated NE levels in bronchoalveolar lavage fluid are closely associated with structural tissue damage (16). Taken together, these findings suggest that excessive neutrophil activation leads to abundant NET formation, while the concomitant release of injurious mediators further exacerbates tissue damage and inflammation. In smoking-related COPD, persistent neutrophil-dominated airway inflammation is a hallmark feature. In 2017, Qiu et al. and Zhang et al. (18,33) reported that tobacco extracts can directly induce NET formation. Within the airways, NETs, together with high mobility group box 1 (HMGB1), act as endogenous danger-associated molecular patterns (DAMPs) that activate dendritic cells and promote the differentiation of T helper (Th)1 and Th17 cells. This process initiates and amplifies adaptive immune responses in the lung, thereby contributing to the persistence of chronic inflammation. Clinical observations indicate that in a subset of patients, COPD symptoms persist even after smoking cessation, which may be related to the role of NETs in sustaining immune activation. Consistently, Zhang et al. (33) demonstrated that sputum from patients with smoking-related COPD during acute exacerbations contains abundant NET-derived components. Collectively, these findings suggest that NETs not only play a pivotal role in the pathogenesis of COPD, but may also serve as potential biomarkers for predicting acute exacerbations and as candidate targets for early therapeutic intervention. Overview of Slit2-Robo signal axis Slit2 is a member of the Slit family and was initially identified as a guidance cue that promotes axonal pathfinding (34). Robo receptors, which belong to the immunoglobulin (Ig) superfamily, serve as the binding partners for Slit proteins. The Slit2-Robo signaling axis plays a critical role in a variety of biological processes, including neural development, tumorigenesis, angiogenesis, and immune regulation (35-37). By engaging distinct receptors, such as Robo1, Robo2, Robo3, and Robo4, Slit2 activates downstream signaling cascades that regulate multiple cellular processes, including migration, differentiation, and proliferation (38). In the context of immune responses, the Slit2-Robo axis modulates immune cell function primarily through two mechanisms: first, by directing the chemotactic migration of immune cells, whereby Slit2 binding to Robo receptors promotes their accumulation at sites of infection or inflammation; and second, by regulating immune cell activation, inhibitory signaling, and cytokine secretion, thereby shaping the overall immune response (39). Slit2 is a highly conserved, secreted glycoprotein that is synthesized by bronchial epithelial cells (Clara cells) in the lung. Structurally, Slit2 comprises an N-terminal signal peptide, four leucine-rich repeat (LRR) domains, nine epidermal growth factor (EGF)-like repeats, and a C-terminal cysteine-rich region. Proteolytic processing of Slit2 yields an N-terminal fragment, containing the LRR domains and part of the EGF-like repeats, and a C-terminal fragment, encompassing the remaining EGF-like repeats and the cysteine-rich region. Both the full-length protein and its cleavage products are secreted into the extracellular space, where they participate in axon guidance and other cell migration processes. Initially, Slit proteins were thought to function predominantly in the central nervous system, where they regulate axonal guidance and neuronal migration, and their expression in neurons and glial cells has been well documented (40,41). With advancing research, Slit has been recognized as a multifunctional signaling molecule that can act both as a silencing cue and as a repulsive factor, thereby modulating cellular branching and extension (40,41). The Slit family comprises three members—Slit-1, Slit-2, and Slit-3—which have been cloned in various model systems (42-44). The Robo receptor family is likewise highly conserved and consists mainly of Robo1 through Robo4, all of which are members of the Ig superfamily (34,45). Throughout evolution from Drosophila to mammals, Robo receptors have exhibited a remarkable degree of structural and functional conservation. Studies of Robo mutants have underscored the central role of Slit/Robo signaling in axonal guidance and cell migration (46,47). In recent years, Slit proteins have been recognized as putative tumor suppressors. Overexpression of Slit has been shown to suppress colony formation in breast cancer cell lines, suggesting an inhibitory role in tumorigenesis (47). Genetic studies have further confirmed the importance of the Slit/Robo complex in breast cancer, demonstrating that Slit genes are frequently inactivated by promoter hypermethylation in patients, thereby impairing their normal function. Although Slit plays a pivotal role in regulating the motility of neurons and leukocytes, the precise downstream signaling pathways remain incompletely defined. Available evidence indicates that Slit2 is the most extensively studied member of the Slit family and acts predominantly through interaction with Robo1. Data show that Slit2 is methylated in approximately 71% of glioma cells, and that its expression is markedly downregulated in tumors harboring this epigenetic modification (48). In addition, the development of lung cancer may be associated with reduced stability of Robo1. Prasad et al. (49) reported that activation of the Slit2-Robo1 signaling pathway can block CXCL12-induced chemotaxis, adhesion, migration, and invasion of breast cancer cells, while concurrently suppressing extracellular matrix secretion. In pancreatic ductal carcinoma and other malignancies, stimulation of this pathway likewise inhibits cancer cell metastasis and angiogenesis. In vitro experiments have demonstrated that recombinant human Slit2 reduces the invasive capacity and angiogenic potential of oral squamous cell carcinoma cells (50). In gastric cancer models, knockdown of Slit2 promotes tumor cell metastasis and growth, which may be linked to activation of the protein kinase B (AKT)/β-catenin signaling pathway (51). With respect to inflammatory regulation, the Slit2-Robo signaling axis plays an important role in directing the migration of inflammatory cells and attenuating the chemotactic responses of neutrophils and T cells, thereby exerting a potential modulatory effect on the overall intensity of inflammation. In pulmonary inflammation, the Slit2-Robo pathway is downregulated in patients with smoking-related COPD, and in tobacco-induced emphysema mouse models, Slit2-Robo1 expression in lung tissue is lower than that in healthy controls (22). However, some studies have suggested that Slit2-Robo signaling may enhance eosinophil chemotaxis and thereby exacerbate pulmonary inflammation (52). Slit2 can also bind to Robo1 and Robo2 to facilitate the recruitment of immune cells, such as neutrophils and macrophages, to sites of inflammation, thereby modulating the magnitude of local immune responses. Downstream signaling molecules of the Slit-Robo signaling pathway Downstream intracellular molecules of Robo signaling In Drosophila models, the Abelson (Abl) tyrosine kinase modulates Robo-mediated repulsive signaling by phosphorylating specific residues within the conserved cytoplasmic region of the Robo receptor. Specifically, the kinase activity of Abl drives phosphorylation of defined residues in Robo, thereby weakening the ability of Robo to bind its ligand Slit. This regulatory mechanism attenuates Robo’s repulsive activity and consequently alters cellular migratory behavior. By phosphorylating residues within the conserved cytoplasmic region, Abl antagonizes Robo-mediated repulsive signaling and thereby exerts a significant influence on nervous system development and cell migration (53). Investigations of this signaling pathway have not only deepened our understanding of the mechanisms underlying nervous system development but have also identified potential therapeutic targets for related diseases. Future studies should further delineate the precise mechanisms by which Abl regulates Slit-Robo signaling and explore its translational potential in human disease, with the ultimate goal of developing more effective therapeutic strategies. Slit-Robo GTPase-activating proteins (srGAPs) srGAPs represent a newer subgroup within the Rho GTPase-activating protein (GAP) family. Experiments by Wong et al. (41) demonstrated that Slit engages srGAPs through an interaction that involves the CC3 motif and C-terminal region of Robo1. More recently, members of the Rho GTPase family—particularly RhoA, Rac1, and Cdc42—have been identified as key signaling components that tightly regulate the actin cytoskeleton during directed migration of mammalian cells (54). GAPs regulate the activity of Rho GTPases by modulating their guanine nucleotide-bound state, either by enhancing the intrinsic GTPase activity or, in cooperation with guanine nucleotide exchange factors, by promoting the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP). Rho GTPases are inactive in their GDP-bound form and become active upon binding GTP. In repulsion assays using migrating neurons from the forebrain subventricular zone, it was found that upon Slit2 binding, Robo1 recruits srGAP1—one of the GAP family members that includes srGAP1, srGAP2, and srGAP3—through direct interaction with its intracellular CC3 motif, leading to inactivation of Cdc42 and RhoA without affecting Rac1 activity. Thus, srGAP1 and Cdc42 play critical roles in the initiation of Slit2-Robo1 signaling. Phosphatidylinositol-3 kinase (PI3K) Wang et al. (55) showed that Slit2 can activate PI3K, a downstream effector in the Slit2-Robo1 signaling pathway, thereby reducing microvessel density in human malignant melanoma A375 cells and markedly inhibiting tumor angiogenesis. In breast cancer-related studies, Slit2 has been validated as a tumor suppressor. Ectopic expression of Slit2 protein in several breast cancer cell lines suppresses cell proliferation and significantly reduces colony-forming capacity. Building on this, Prasad et al. (49) further demonstrated that the Slit2-Robo1 signaling system, via activation of PI3K, inhibits CXCL12-induced chemotaxis and migration. Slit may modulate protein tyrosine kinase pathways to influence the complex assembly of cytoskeletal proteins, thereby regulating the dynamics of focal adhesions and ultimately altering cell motility (56). These processes are critical for directed cell migration. Our observations indicate that Slit can effectively inhibit Src kinase activity, which is known to participate in the regulation of focal adhesion dynamics. Downstream matrix-associated components of Src signaling, such as focal adhesion kinase (FAK), RAFTK (Pyk2), and paxillin, are essential constituents of focal adhesion complexes (56). In breast cancer models, Slit markedly reduces CXCL12-induced chemotaxis, adhesion, and chemoinvasion, as well as the secretion of MMP-2 and MMP-9, which are closely associated with breast cancer cell invasion and metastasis. By attenuating these CXCL12-driven processes, Slit exerts a potential inhibitory effect on tumor cell migration and invasion and may further diminish metastatic capacity by reducing MMP-2 and MMP-9 secretion. These findings provide a new theoretical basis for breast cancer therapy and suggest that the Slit signaling axis may serve as a promising target for limiting tumor invasion and metastasis. TLR3-SLIT2 axis in endothelium Cancer cells exploit innate RNA-sensing mechanisms to activate chemotactic signaling pathways in endothelial cells, thereby promoting intravascular migration and metastasis. Studies have shown that double-stranded RNA (dsRNA) released by tumor cells acts as an upstream signal that binds to the RNA-sensing receptor TLR3 and induces SLIT2 expression in endothelial cells. The SLIT2 secreted by endothelial cells, together with its receptor ROBO1, cooperatively promotes the migration of cancer cells into the vasculature. Deletion of the Slit2 gene in endothelial cells markedly suppresses metastatic dissemination in mouse models of breast and lung cancer, suggesting that endothelial cells provide guidance cues during tumor metastasis. Moreover, the impact of Slit2 on tumor progression appears to be context-dependent, with its expression exerting either pro-metastatic or tumor-suppressive effects depending on the cellular source. As the principal sensor for dsRNA, TLR3 mediates the regulation of endothelial SLIT2 expression by tumor-derived RNA. Early studies have shown that Slit2 expression in tumor cells is silenced via promoter hypermethylation or allelic loss, further supporting its role as a putative tumor suppressor and underscoring its importance as a regulatory node within the TLR3 signaling pathway (22,53,57). Conclusions Increasing attention has been directed toward the role of the Slit2-Robo signaling axis in COPD-related chronic inflammation, particularly in the context of tobacco exposure-induced inflammatory responses. Current evidence suggests that this pathway may participate in the regulation of several key pathogenic processes, including immune cell migration, persistence of inflammation, and tissue repair. In particular, the Slit2-Robo axis may serve as an important regulatory node in the continuous pathological cascade of inflammatory cell migration, NET expansion, and subsequent tissue injury and remodeling. CS exposure can induce oxidative stress and airway epithelial barrier injury, thereby reshaping the pulmonary immune microenvironment, promoting the release of chemotactic mediators such as IL-8, and upregulating endothelial adhesion molecules, which collectively drive persistent neutrophil recruitment into the airways and lung parenchyma. Within the local lesional microenvironment, neutrophils may undergo aberrant activation, releasing ROS, NE, and MPO, while also promoting the formation of NETs. These events further aggravate epithelial cell injury, extracellular matrix degradation, and disruption of the mucus microenvironment. Concurrently, NETs and their associated DAMPs may further activate macrophages and dendritic cells and promote polarization toward Th1/Th17-type immune responses, ultimately establishing a cascade of amplification that sustains chronic inflammation. In this context, the Slit2-Robo1 signaling axis may exert an important negative regulatory effect. Available studies have shown that, following binding of Slit2 to Robo1, the migration and chemotactic behavior of inflammatory cells and other effector cells may be modulated directly or indirectly through signaling pathways such as PI3K. Moreover, the activity of this signaling axis may also be influenced by upstream or associated regulators, including Abl tyrosine kinase, srGAPs, and TLR3. Taken together, the Slit2-Robo axis may impose a constraining effect on inflammatory responses by modulating cytokine and chemokine networks, thereby attenuating tissue injury mediated by NE, MPO, and ROS. In NET-related pathological processes, the Slit2-Robo pathway may reduce sustained NET release by suppressing aberrant neutrophil migration and excessive activation, thereby interrupting the chronic inflammatory positive-feedback loop formed by NETs, DAMPs, and adaptive immune amplification. Accordingly, impairment or downregulation of Slit2-Robo signaling may be associated with persistent inflammation, dysregulated tissue repair, and aggravated airway/parenchymal remodeling in COPD. A schematic overview of its potential mechanisms is presented in Figure 1. Based on the currently available evidence, this signaling axis appears to have value both in mechanistic interpretation and in potential translational application. Schematic illustration of the immune role of the Slit2/Robo signaling axis in COPD. Abl, Abelson; COPD, chronic obstructive pulmonary disease; H3, histones-3; HMGB1, high mobility group box 1; IL-8, interleukin-8; LPS, lipopolysaccharide; MPO, myeloperoxidase; NE, neutrophil elastase; NETs, neutrophil extracellular traps; PI3K, phosphatidylinositol-3 kinase; PMA, phorbol 12-myristate 13-acetate; Robo, roundabout; ROS, reactive oxygen species; srGAPs, Slit-Robo GTPase-activating proteins; TH1/TH17, T helper 1/17 cells. However, the current evidence base remains largely preclinical, and direct validation in human COPD is still insufficient. In addition, some reported effects of the Slit2-Robo signaling axis appear to be context-dependent or somewhat inconsistent across studies, particularly with respect to inflammatory cell recruitment, tissue repair, and remodeling. These discrepancies may be attributable to differences in experimental models, exposure conditions, disease stage, receptor subtype expression, and the local inflammatory microenvironment. Therefore, future investigations should prioritize validation of these findings in well-characterized human COPD cohorts, clarify the cell-specific and stage-specific mechanisms of this signaling axis, and evaluate its clinical feasibility as both a biomarker and a therapeutic target. Before the Slit2-Robo pathway can be considered a reliable target for precision intervention in smoking-related lung disease, more rigorous clinical and translational studies will be required. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0136/prf